SI1140935T1 - 1,2-annelated quinoline derivatives - Google Patents

1,2-annelated quinoline derivatives

Info

Publication number
SI1140935T1
SI1140935T1 SI9930350T SI9930350T SI1140935T1 SI 1140935 T1 SI1140935 T1 SI 1140935T1 SI 9930350 T SI9930350 T SI 9930350T SI 9930350 T SI9930350 T SI 9930350T SI 1140935 T1 SI1140935 T1 SI 1140935T1
Authority
SI
Slovenia
Prior art keywords
quinoline derivatives
annelated quinoline
annelated
derivatives
quinoline
Prior art date
Application number
SI9930350T
Other languages
English (en)
Slovenian (sl)
Inventor
Patrick Rene Janssen-Cilag S.A. Angibaud
Marc Gaston Janssen-Cilag S.A. VENET
Xavier Marc Janssen-Cilag S.A. BOURDREZ
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI1140935T1 publication Critical patent/SI1140935T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
SI9930350T 1998-12-23 1999-12-17 1,2-annelated quinoline derivatives SI1140935T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98204444 1998-12-23
EP99969220A EP1140935B1 (en) 1998-12-23 1999-12-17 1,2-annelated quinoline derivatives
PCT/EP1999/010214 WO2000039082A2 (en) 1998-12-23 1999-12-17 1,2-annelated quinoline derivatives

Publications (1)

Publication Number Publication Date
SI1140935T1 true SI1140935T1 (en) 2003-10-31

Family

ID=8234557

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930350T SI1140935T1 (en) 1998-12-23 1999-12-17 1,2-annelated quinoline derivatives

Country Status (32)

Country Link
US (2) US6458800B1 (cs)
EP (1) EP1140935B1 (cs)
JP (1) JP4725940B2 (cs)
KR (2) KR100712226B1 (cs)
CN (1) CN1178938C (cs)
AR (1) AR021995A1 (cs)
AT (1) ATE240327T1 (cs)
AU (1) AU765437B2 (cs)
BG (1) BG65124B1 (cs)
BR (1) BR9916827A (cs)
CA (1) CA2355717C (cs)
CZ (1) CZ302374B6 (cs)
DE (1) DE69907964T2 (cs)
DK (1) DK1140935T3 (cs)
EA (1) EA004542B1 (cs)
EE (1) EE04962B1 (cs)
ES (1) ES2200591T3 (cs)
HK (1) HK1038746B (cs)
HR (1) HRP20010454B1 (cs)
HU (1) HU229404B1 (cs)
ID (1) ID29241A (cs)
IL (2) IL143859A0 (cs)
NO (1) NO318922B1 (cs)
PL (1) PL199080B1 (cs)
PT (1) PT1140935E (cs)
SI (1) SI1140935T1 (cs)
SK (1) SK286072B6 (cs)
TR (1) TR200101961T2 (cs)
TW (1) TW531533B (cs)
UA (1) UA71592C2 (cs)
WO (1) WO2000039082A2 (cs)
ZA (1) ZA200105136B (cs)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396865C (en) * 2000-02-04 2009-04-14 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating breast cancer
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
EP1261348A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
WO2001064246A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
CA2397694A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations
AU2001246478A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
EP1267872A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001256166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525234A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
EP1322644A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
EP1322636A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
AU2001293826A1 (en) * 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974438B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
EA007464B1 (ru) * 2000-10-02 2006-10-27 Янссен Фармацевтика Н.В. Антагонисты метаботропных рецепторов глутамата
DE60139080D1 (de) * 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
JP4231691B2 (ja) * 2000-11-28 2009-03-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 炎症性腸疾患の治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
DE60117847T2 (de) 2000-12-27 2006-11-16 Janssen Pharmaceutica N.V. Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US20040157773A1 (en) * 2001-04-25 2004-08-12 End David William Farnesyl protein transferase inhibitors for treating cachexia
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
CA2468015A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2002358677B2 (en) 2001-12-19 2008-02-07 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en) 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
BR0308945A (pt) * 2002-03-29 2005-01-04 Janssen Pharmaceutica Nv Derivados radiomarcados de quinolina e quinolinona e uso dos mesmos como ligantes para receptores de glutamato metabotrópicos
JP4384505B2 (ja) * 2002-04-15 2009-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
US7358259B2 (en) 2003-09-26 2008-04-15 Rigel Pharmaceuticals, Inc. HCV inhibitors and methods of using them
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
SI2362218T1 (sl) 2004-11-05 2014-12-31 Janssen Pharmaceutica N.V. Postopki za spremljanje učinkovitosti inhibitorjev farneziltransferaze
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
DE102006012545A1 (de) * 2006-03-18 2007-09-27 Sanofi-Aventis Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
EP2021335B1 (en) * 2006-04-20 2011-05-25 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
RU2014136226A (ru) * 2012-02-13 2016-04-10 Ф.Хоффманн-Ля Рош Аг Производные имидазолилкетона в качестве ингибиторов альдостеронсинтазы
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (cs) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
EA201590750A1 (ru) 2012-10-16 2015-09-30 Янссен Фармацевтика Нв СВЯЗАННЫЕ С ФЕНИЛОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγT
PE20150778A1 (es) 2012-10-16 2015-05-23 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de ror-gamma-t
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CN105848483A (zh) 2013-10-15 2016-08-10 詹森药业有限公司 RORγt 的喹啉基调节剂
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3285768B1 (en) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
ES2741782T3 (es) 2015-08-17 2020-02-12 Kura Oncology Inc Métodos para tratar pacientes con cáncer a partir de inhibidores de la farnesiltransferasa
US10745370B2 (en) * 2016-03-23 2020-08-18 Mackay Memorial Hospital Farnesyl transferase inhibitors and uses thereof
SG11201903786UA (en) 2016-11-03 2019-05-30 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
UA57717C2 (uk) * 1995-12-08 2003-07-15 Янссен Фармацевтика Н.В. Похідні (імідазол-5-іл)метил-2-хінолінону, спосіб їх отримання та фармацевтична композиція на їх основі
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ES2289783T3 (es) * 1997-04-25 2008-02-01 Janssen Pharmaceutica N.V. Quinazolinonas que inhiben la farnesiltransferasa.
NZ501401A (en) * 1997-06-02 2002-03-28 Janssen Pharmaceutica Nv (Imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

Also Published As

Publication number Publication date
BR9916827A (pt) 2001-10-16
PL349504A1 (en) 2002-07-29
ES2200591T3 (es) 2004-03-01
IL143859A0 (en) 2002-04-21
KR20010087396A (ko) 2001-09-15
EE200100318A (et) 2002-10-15
HUP0104582A3 (en) 2002-12-28
DE69907964D1 (de) 2003-06-18
ID29241A (id) 2001-08-16
AU765437B2 (en) 2003-09-18
CZ20012142A3 (cs) 2002-01-16
BG105631A (en) 2002-02-28
US20030119843A1 (en) 2003-06-26
UA71592C2 (uk) 2004-12-15
CN1331693A (zh) 2002-01-16
DE69907964T2 (de) 2004-02-19
IL143859A (en) 2008-04-13
EP1140935A2 (en) 2001-10-10
HU229404B1 (en) 2013-12-30
NO20013088L (no) 2001-06-21
NO318922B1 (no) 2005-05-23
EP1140935B1 (en) 2003-05-14
SK286072B6 (sk) 2008-02-05
AR021995A1 (es) 2002-09-04
HUP0104582A2 (hu) 2002-04-29
EA200100708A1 (ru) 2001-12-24
ZA200105136B (en) 2002-06-21
CA2355717A1 (en) 2000-07-06
KR100712226B1 (ko) 2007-04-27
AU2795300A (en) 2000-07-31
PL199080B1 (pl) 2008-08-29
WO2000039082A2 (en) 2000-07-06
CZ302374B6 (cs) 2011-04-20
TR200101961T2 (tr) 2001-12-21
HK1038746A1 (en) 2002-03-28
CA2355717C (en) 2011-02-08
KR100818541B1 (ko) 2008-04-02
BG65124B1 (bg) 2007-03-30
EE04962B1 (et) 2008-02-15
WO2000039082A3 (en) 2000-10-26
JP4725940B2 (ja) 2011-07-13
KR20060117380A (ko) 2006-11-16
JP2002533435A (ja) 2002-10-08
HK1038746B (en) 2003-09-05
US6914066B2 (en) 2005-07-05
EA004542B1 (ru) 2004-06-24
DK1140935T3 (da) 2003-09-01
NO20013088D0 (no) 2001-06-21
ATE240327T1 (de) 2003-05-15
US6458800B1 (en) 2002-10-01
PT1140935E (pt) 2003-10-31
SK8732001A3 (en) 2002-02-05
HRP20010454A2 (en) 2002-06-30
CN1178938C (zh) 2004-12-08
HRP20010454B1 (en) 2004-06-30
TW531533B (en) 2003-05-11

Similar Documents

Publication Publication Date Title
HRP20010454B1 (en) 1,2-annelated quinoline derivatives
ZA200007593B (en) Quinoline Derivatives.
IL143782A0 (en) Quinoline derivatives
IL138160A0 (en) Quinoline derivatives
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
IL141226A0 (en) 1h-imidazopyridine derivatives
ZA99254B (en) Benzosulfone derivatives.
PL345540A1 (en) Thiobenzimidazole derivatives
PL345389A1 (en) Quinoline derivatives
GB9809664D0 (en) a-Ketoamide derivatives
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
EG23802A (en) 2-Phenylpyran-4-one derivatives
ZA991550B (en) Cyclohexanediole derivatives.
GB9827729D0 (en) Thieno-indole derivatives
EP1061912A4 (en) PHENANTHROFURANDERIVATE
IL139276A0 (en) Cyclohexenondioxthio chromanoyl derivatives
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
ZA200101452B (en) 1-H-Imidazopyridine derivatives.
ZA9811564B (en) Derivatives of 1,3,4-oxadiazolone
GB9815537D0 (en) 2,6-Quinolines
GB9816279D0 (en) Arylthiazolidinedione derivatives